Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease

ADPKD Clinical Trial

— METROPOLIS  

Official title:

Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease. A Phase 3a, Indipendent, Multicentre, Two Parallel Arms, Randomized Controlled Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03764605
• Other study ID #: Eudract2018-000477-77
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: January 30, 2019
• Est. completion date: January 30, 2022

Study information

• Verified date: December 2018
• Source: Azienda Ospedaliero-Universitaria Consorziale
• Contact: Loreto Gesualdo
• Phone: +390805594040
• Email: loretoge60[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disorder occurring in 1:400-1:1.000 live births and affects 4 to 6 million persons worldwide and about 205.000 people in Europe (EU). This figure is equivalent to 4 in 10.000 people and thus below the prevalence threshold of 5 in 10.000 used to designate a disease as rare in EU.

Renal cyst development and expansion in ADPKD involves both fluid secretion and abnormal proliferation of cyst-lining epithelial cells. The chloride channel of the cystic fibrosis transmembrane conductance regulator (CFTR) participates in secretion of cyst fluid, and the mammalian target of rapamycin (mTOR) pathway may drive proliferation of cyst epithelial cells. CFTR and mTOR are both negatively regulated by AMP-activated protein kinase (AMPK). Metformin, a drug widely used, is a pharmacological activator of AMPK. The investigators found that metformin stimulates AMPK, resulting in inhibition of both CFTR and the mTOR pathways. Metformin induces significant arrest of cystic growth in both in vitro and ex vivo models of renal cystogenesis. In addition, metformin administration produces a significant decrease in the cystic index in two mouse models of ADPKD. These results suggest a possible role for AMPK activation in slowing renal cystogenesis as well as the potential for therapeutic application of metformin in the context of ADPKD.

Thus this study aims to evaluate metformin efficacy in slowing renal cystogenesis in ADPKD as compared to the actual gold standard (Tolvaptan).

Description:

Objective of the study is to assess if a two-year course of 1500 mg oral metformin is effective and safe in treatment of ADPKD, as compared to the actual gold-standard therapy, tolvaptan (Jinarc®) This is a phase 3a, independent, multi-centre, parallel arms, randomized controlled trial comparing efficacy and safety of metformin and tolvaptan in ADPKD.

This trial will enroll approximately 150 tolvaptan and metformin naïve subjects affected by Type I-truncating ADPKD, as these subjects have grater probability of progression.

The trial contemplates a 2 weeks screening period (included in a 9 months total recruitment period) during which 3 visits have to be collected (the 1st and the 2nd in three days, and the 3rd after biochemical analyses performed during the first two visits have been reviewed). The subject's eligibility for the trial will be confirmed by the mean of eGFR calculated from the 2 pre-treatment, central-lab, serum creatinine assessments. Longer screening periods (up to 4 additional weeks) are acceptable for subjects needing stabilization after changing or discontinuing other treatments, especially anti-hypertensives and diuretics.

Once eligibility is assessed, patients will undergo non-contrast enhanced CT-scan of kidneys (if not performed within six months prior to randomization).

Randomization visit will occur on Day -29. During this visit patients will be randomized (in a ratio 1:1 tolvaptan:metformin) to each arm of treatment and will start an IMP titration period (3 weeks from -28 to -8). Subjects not tolerating the minimum IMP dose will be considered "Titration failures" and will complete End of Treatment (EoTx) visit assessments and will be followed up after 7 days by phone call to assess any ongoing AEs. Subjects tolerating the minimum IMP dose enter the unblind run-in period (1 week from Day -7 to -1). During the "Run-in" phase, subjects will continue on a stable IMP dose to confirm tolerability over a longer period. At the end of the run-in period (Day -1), subjects not tolerating the minimum IMP dose will be considered "Run-in failures" and will complete EoTx visit assessments and will be followed up after 7 days by phone call to assess any ongoing AEs. Subjects completing the run-in will start the open-label 24 months treatment period, during which visits will be collected three-monthly. At the end of the 24th month, and in case of early treatment cessation, follow-up period (3 weeks from +8 to +21) will start, during which 2 visits have to be collected. No IMP will be administered during this period.

This trial will enroll approximately 150 tolvaptan and metformin naïve subjects and will be conducted in about 11 Italian Hospital Nephrology Departments The investigators plan to recruit a total of 150 patients which are currently within the reach of the network coordinated by the proponent and composed by 11 Nephrology Centres. This network treats a total of 1500 (already genetically studied) patients of which the investigators expect (based on standard response rates recognized in the population) acceptance to participate in the study to a value of approximately 40% of patients that will be then allocated to the experimental and control intervention.

The selected sample is adequate to evaluate a significant reduction in the slope of eGFR at 2 years by 10%, which is a clinically relevant piece of information at the current state of knowledge, as well as a complete assessment of the benefits-harms trade-off of the two interventions.

The trial has a 36 months overall duration, that include a 9 months recruitment period; has a 2 weeks duration, it is included in the 9 months recruitment period. The treatment period has a 25 months duration. Each month lasts 28 days. It includes the 3 weeks titration period and the 1 week run-in period.

The post-treatment follow-up: lasts 21 days. The total Study Duration is of about 3 years.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 150
• Est. completion date: January 30, 2022
• Est. primary completion date: September 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Men and women aged between 18 and 50 years

2. eGFR (CKD-EPI) = 45 ml/min/1,73 m2

3. Genetic Diagnosis of Type I ADPKD truncating mutation

4. Signed and dated informed consent

Exclusion Criteria:

1. Women of childbearing potential (WOCBP) who do not agree to practice 2 different methods of birth control or remain abstinent during the trial and for 30 days after the last dose of IMP. If employing birth control, 2 of the following precautions must be used: vasectomy of partner, tubal ligation, vaginal diaphragm, intrauterine device, birth control implant, condom, or sponge with spermicide. Non-childbearing potential in women is defined as female subjects who are surgically sterile (ie, have undergone bilateral oophorectomy or hysterectomy) or female subjects who have been postmenopausal for at least 12 consecutive months.

2. Women who are breast-feeding and/or who have a positive pregnancy test result prior to receiving investigational medical product (IMP).

3. Treatment with acarbose, guar gum, cimetidin, phenprocoumon, oral anticoagulants, thrombolytic drugs, diuretics, ranolazin, cephalexin.

4. Evidence of active systemic or localized major infection at the time of screening.

5. Hepatic impairment or liver function abnormalities other than that expected for ADPKD with typical cystic liver disease during the screening period as defined by:

• AST O ALT >8x UNL

• AST O ALT >5x UNL >2 WEEKS

• AST O ALT >3x UNL E BT >2x UNL OR INR >1,5

• AST O ALT >3x UNL E SIGNS AND SYMPTOMS OF LIVER DAMAGE (fatigue, anorexy, nausea, vomiting, right hypocondrium pain, fever, jaundice, skin rash, itching)

6. Acute or chronic disease causing tissue hypoxia (e.g.: myocardial failure, severe arythmias, myocardial infarction, respiratory failure, liver failure, alcohol acute intoxication, alcoholism, dehydration).

7. Previously diagnosed diabetes already in treatment with other hypoglycemic drugs.

8. Ongoing breast feeding.

9. Use of any other investigational drug or treatment up to 4 weeks before enrollment and during the treatment phase.

10. Known hypersensitivity to metformin and its derivatives.

11. Psychiatric disorders and any condition that might prevent full comprehension of the purposes and risks of the study.

12. Malignancies within three years before enrolment in the study.

13. HIV, HBV, HCV infection.

14. Urinary tract obstruction.

Related Conditions & MeSH terms

• ADPKD
• Kidney Diseases
• Polycystic Kidney Diseases
• Polycystic Kidney, Autosomal Dominant

Intervention

Drug:
• Metformin
Patieny will be treated by using Metformin from 500 mg a day to 500 mg thrice a day.
• Tolvaptan
Patients will be treated with tolvaptan from 45 mg + 15 mg a day to 90 mg + 30 mg a day

Locations

Country	Name	City	State
Italy	AOUC "Policlinico"	Bari
Italy	AOUConsorziale Policlinico Di Bari	Bari

Sponsors (1)

Lead Sponsor	Collaborator
Azienda Ospedaliero-Universitaria Consorziale

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Blood pressure	mmHg	36 months
Other	Post void body weight	Kg	36 months
Other	Change from serum creatinine baseline	mg/dl	36 months
Other	Serum sodium	mg/dl	36 months
Other	Blood venous gas lactate levels	mmol/l	36 months
Other	Bolood Glucose levels	mg/dl	36 months
Other	Vitamin B12 deficency	pg/ml	36 months
Primary	Glomerular Filtration Rate (estimated by CKD-Epi formula) variation	Primary outcome of the study is to evaluate the difference between Metformin and Tolvaptan in annualized slope of eGFR (CKD-EPI) for individual subjects, that will be calculated using an appropriate baseline and post-randomization assessment.	25 months
Secondary	Total Kidney Volume variation (measured by non contrast enhanced Kidney CT scan)	The key secondary endpoint is the percent change from baseline in htTKV as measured by CT-scan at 24 months.	25 months